{
  "position_summary": "Long ACME (mid-cap medtech), 3% portfolio weight, 12–18 month horizon. Thesis is that procedure growth and a new surgical platform will drive mid-teens top-line growth and operating leverage.",
  "factor_exposures": [
    "Overweight healthcare equipment vs benchmark.",
    "Tilted to mid-cap growth with modest quality bias.",
    "Net long US dollar revenue exposure with some euro costs."
  ],
  "event_calendar": [
    "Next earnings call in six weeks.",
    "FDA decision on a new indication for the surgical platform expected in 3–4 months.",
    "Major industry conference in ~2 months where management will present updated data."
  ]
}
